SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer

Modern Pathology

Volumn 22, Issue 7, 2009, Pages 922-932

  Nosho, Katsuhiko ^a   Shima, Kaori ^a   Irahara, Natsumi ^a   Kure, Shoko ^a   Firestein, Ron ^a,b   Baba, Yoshifumi ^a   Toyoda, Saori ^a   Chen, Li ^b   Hazra, Aditi ^b,c   Giovannucci, Edward L ^b,c   Fuchs, Charles S ^a,b   Ogino, Shuji ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acetylation; Colon cancer; Epigenetics; HDAC; Sir2; Sirtuin

Indexed keywords

FATTY ACID SYNTHASE; HISTONE DEACETYLASE; SIRTUIN 1;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; CPG ISLANDS; DATABASES, FACTUAL; DNA METHYLATION; DNA, NEOPLASM; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; SIRTUINS;

EID: 67650691722     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.49     Document Type: Article

References (58)

1. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008;3:28-37.
2. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8: 286-298.
3. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004;305: 390-392.
4. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell 2005;120:473-482.
5. Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007; 404:1-13.
6. Bishop NA, Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet 2007;8:835-844.
7. Olaharski AJ, Rine J, Marshall BL, et al. The flavoring agent dihydrocoumarin reverses epigenetic silencing and inhibits sirtuin deacetylases. PLoS Genet 2005;1:e77.
8. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000;14:1021-1026.
9. Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature 2000;408:255-262.
10. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 2004;306:2105-2108.
11. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001;107:149-159.
12. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001;107:137-148.
13. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002;21:2383-2396.
14. Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004;116:551-563.
15. Chen WY, Wang DH, Yen RC, et al. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53- dependent DNA-damage responses. Cell 2005;123: 437-448.
16. Pruitt K, Zinn RL, Ohm JE, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40.
17. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008;3:e2020.
18. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-8686.
19. Issa JP, Shen L, Toyota M. CIMP, at last. Gastroenterology 2005;129:1121-1124.
20. Grady WM. CIMP and colon cancer gets more complicated. Gut 2007;56:1498-1500.
21. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008;268:177-186.
22. Whitehall VL, Wynter CV, Walsh MD, et al. Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer. Cancer Res 2002;62:6011-6014.
23. Samowitz W, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-845.
24. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793.
25. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn 2008;10: 13-27.
26. Derks S, Postma C, Carvalho B, et al. Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 2008;29: 434-439.
27. Stunkel W, Peh BK, Tan YC, et al. Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2007;2:1360-1368.
28. Colditz GA, Hankinson SE. The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer 2005;5:388-396.
29. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX- 2. N Engl J Med 2007;356:2131-2142.
30. Ogino S, kawasaki T, Kirkner GJ, et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 2007;9:305-314.
31. Ogino S, Nosho K, Kirkner GJ, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 2008;100:1734-1738.
32. Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
33. Ogino S, Kawasaki T, Brahmandam M, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-421.
34. Ogino S, Kawasaki T, Kirkner GJ, et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-588.
35. Nosho K, Kawasaki T, Ohnishi M, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10: 534-541.
36. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-1006.
37. Eads CA, Danenberg KD, Kawakami K, et al. Methy- Light: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
38. Ogino S, kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217.
39. Nosho K, Irahara N, Shima K, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large populationbased sample. PLoS ONE 2008;3:e3698.
40. Ogino S, Kawasaki T, Nosho K, et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 2008;122: 2767-2773.
41. Yang AS, Estecio MR, Doshi K, et al. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
42. Ogino S, kawasaki T, Kirkner GJ, et al. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22.
43. Ogino S, Nosho K, Meyerhardt JA, et al. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J Clin Oncol 2008;26: 5713-5720.
44. Ogino S, Brahmandam M, Cantor M, et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19: 59-68.
45. Kawasaki T, Nosho K, Ohnishi M, et al. Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. Neoplasia 2007;9:569-577.
46. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989;8:551-561.
47. Dong Y, Wang J, Sheng Z, et al. Downregulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol 2009;22:151-160.
48. Hamilton SR. Targeted therapy of cancer: new roles for pathologists in colorectal cancer. Mod Pathol 2008;21(Suppl 2):S23-S30.
49. Lugli A, Tzankov A, Zlobec I, et al. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol 2008;21:1403-1412.
50. Sung CO, Seo JW, Kim KM, et al. Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol 2008;21:1533-1541.
51. Ye SR, Yang H, Li K, et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007;20:375-383.
52. Minoo P, Zlobec I, Baker K, et al. Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 2007;20:331-338.
53. Kaifi JT, Reichelt U, Quaas A, et al. L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol 2007;20:1183-1190.
54. Kimura A, Umehara T, Horikoshi M. Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing. Nat Genet 2002;32:370-377.
55. Suka N, Luo K, Grunstein M. Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet 2002;32:378-383.
56. Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 2006;38:566-569.
57. Konishi K, Issa JP. Targeting aberrant chromatin structure in colorectal carcinomas. Cancer J 2007;13:49-55.
58. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 2007;8:829-833.